JGO Weekly Summary (April 10, 2025)

JGO Weekly Summary (July 6, 2025)

This episode summarizes a cross-sectional study from Central China on HPV genotype distribution and infection risk factors. Ye Chen and colleagues found that HPV52, 16, and 58 were most common, with infection peaks in young and older women. High-risk factors included diabetes, anxiety, low work intensity, and multiple sexual partners. Condom use and HPV vaccination were protective. The study advocates for integrative prevention strategies including psychosocial and metabolic health management.

JGO Weekly Summary (May 11, 2025)

In this episode of the JGO Podcast, we explore a recent study from Peking Union Medical College Hospital examining the role of adjuvant surgery in patients with high-risk chemorefractory or relapsed gestational choriocarcinoma who achieve complete remission following anti-PD-1 therapy. The retrospective analysis of 43 patients reveals no significant difference in survival outcomes between those who underwent surgery and those who did not, raising important questions about the necessity of surgical intervention in this setting. We discuss the implications of these findings in light of current treatment guidelines and emerging data on immunotherapy in gestational trophoblastic neoplasia.

JGO Weekly Summary (April 29, 2025)

This episode features an in-depth discussion of the Asian cohort analysis from the AtTEnd/ENGOT-EN7 phase III trial, which evaluated atezolizumab in combination with carboplatin and paclitaxel for advanced or recurrent endometrial carcinoma. While atezolizumab improved progression-free survival in mismatch repair-deficient tumors across both Asian and non-Asian populations, it showed no benefit—and potential harm—in mismatch repair-proficient Asian patients. The analysis also revealed a higher incidence of severe adverse events among Asians receiving atezolizumab. These findings highlight the importance of considering ethnic differences in treatment response and toxicity in future clinical trials.

JGO Weekly Summary (April 22, 2025)

In this episode, we review findings from the Japan subset of the DUO-E phase III trial, led by Shin Nishio and colleagues, which evaluated durvalumab with or without olaparib following chemotherapy in patients with newly diagnosed advanced or recurrent endometrial cancer. The study demonstrated a progression-free survival benefit in Japanese patients consistent with the global population, with a median of 15.1 months in the durvalumab plus olaparib arm compared to 9.5 months in the control arm. Safety outcomes were manageable and aligned with known profiles of the treatments. These results support durvalumab-based regimens as promising first-line options for Japanese patients.

JGO Weekly Summary (April 10, 2025)

In this episode, we discuss the final analysis of the KEYNOTE-826 subgroup study led by Dr. Yong-Man Kim, evaluating pembrolizumab plus chemotherapy with or without bevacizumab in East Asian patients with persistent, recurrent, or metastatic cervical cancer. The study demonstrated substantial improvements in progression-free and overall survival compared to placebo, with median progression-free survival reaching 18.0 months versus 10.4 months in the overall population, and 29.3 versus 10.9 months in patients with PD-L1 expression. Safety was consistent with the known profile of pembrolizumab. These findings support its use as a standard of care in this population.